Rice Hall James & Associates LLC Purchases Shares of 43,735 Lantheus Holdings, Inc. $LNTH

Rice Hall James & Associates LLC purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 43,735 shares of the medical equipment provider’s stock, valued at approximately $4,852,000. Rice Hall James & Associates LLC owned approximately 0.07% of Lantheus at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. Versor Investments LP acquired a new position in Lantheus during the fourth quarter valued at approximately $519,000. Reinhart Partners LLC. grew its stake in Lantheus by 2.2% in the second quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock valued at $177,437,000 after purchasing an additional 34,501 shares in the last quarter. M&T Bank Corp acquired a new position in shares of Lantheus during the 4th quarter worth approximately $539,000. Epoch Investment Partners Inc. raised its stake in shares of Lantheus by 59.4% during the 1st quarter. Epoch Investment Partners Inc. now owns 649,751 shares of the medical equipment provider’s stock worth $49,284,000 after purchasing an additional 242,222 shares in the last quarter. Finally, First Trust Advisors LP raised its stake in shares of Lantheus by 287.6% during the 1st quarter. First Trust Advisors LP now owns 60,258 shares of the medical equipment provider’s stock worth $4,571,000 after purchasing an additional 44,713 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $100.91 on Tuesday. The company has a current ratio of 3.06, a quick ratio of 2.89 and a debt-to-equity ratio of 0.43. Lantheus Holdings, Inc. has a 12 month low of $49.67 and a 12 month high of $111.86. The stock has a 50 day moving average of $104.24 and a 200-day moving average of $89.57. The company has a market capitalization of $6.59 billion, a P/E ratio of 24.37 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The business had revenue of $388.18 million for the quarter, compared to analysts’ expectations of $363.23 million. During the same quarter in the prior year, the business earned $1.57 EPS. The firm’s revenue for the quarter was up 2.7% on a year-over-year basis. As a group, equities research analysts predict that Lantheus Holdings, Inc. will post 4.5 EPS for the current year.

Analysts Set New Price Targets

LNTH has been the subject of several recent analyst reports. B. Riley Financial downgraded Lantheus from a “buy” rating to a “neutral” rating in a report on Monday. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. William Blair set a $102.50 price target on shares of Lantheus in a research note on Monday, August 3rd. TD Cowen cut shares of Lantheus from a “buy” rating to a “hold” rating and cut their price target for the company from $110.00 to $102.50 in a research note on Monday, August 3rd. Finally, Leerink Partners set a $102.50 price objective on shares of Lantheus in a research note on Monday, August 3rd. Four investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, Lantheus has an average rating of “Hold” and a consensus price target of $108.11.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.